Nutritional Supplement Impact on Metabolic Parameters

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open label study seeks to study the effects of a nutritional supplement on inflammatory markers, metabolic parameters, and safety in subjects compared to baseline after taking supplement for 2 and 4 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors

NCT00010829

Cardiovascular Diseases Osteoporosis Breast Cancer +1 more

COMPLETED PHASE2

Use of Nutraceuticals in Clinical Practice

NCT04161859

Dyslipidemias Diabetes Mellitus, Type 2 Hypertension

COMPLETED

Oral Nutritional Supplement Effect on HDL Function

NCT04529174

HDL

COMPLETED NA

Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices

NCT00661856

Osteoporosis

COMPLETED NA

Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health

NCT03146312

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary endpoint will be to determine if nutritional supplement decreases the metabolic parameter of triglycerides. Numerous studies have demonstrated the efficacy of fish oil on reducing triglycerides in subjects taking fish oil at similar doses provided in our product (see references).

Additional metabolic parameters will be measured as secondary endpoints, including abdominal obesity, HDL cholesterol, blood pressure, fasting glucose, haemoglobin A1c, skin glycation (AGEs), pulse wave velocity, skin carotenoids, serum 25(OH)D concentrations, weight, and LDL density, particle size and number. The novel nutritional supplement contains many nutrients that have been shown to improve metabolic parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Other Endocrine/Nutritional/Metabolic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nutritional Supplement Blend

The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.

Group Type EXPERIMENTAL

Nutritional Supplement Blend

Intervention Type DIETARY_SUPPLEMENT

It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nutritional Supplement Blend

It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject male or female between the ages of 30-70 at the time of informed consent.
2. Fasting Blood Glucose between 90 and 125mg/dL in the serum and 2 additional parameters at screening:

* Abdominal obesity defined by \>102 cm (\>40in) waist circumference in men and \>88cm (\>35in) waist circumference in women, or
* Triglycerides ≥ 150mg/dL, or
* HDL cholesterol \<40 mg/dL in men and \<50 mg/dL in women
3. Hemoglobin A1C less than 6.5% at screening
4. BMI \>27kg/m2
5. Blood Pressure \<150/90 mm Hg
6. Subject is willing and able to comply with study restrictions, procedures, and assessments.
7. Subject is able to swallow product without difficulty.
8. Subject is willing to fast for 8h prior to blood draw at screening, baseline, 2 month, and 4 month visits.
9. Subject is willing to maintain usual diet and physical activity for the duration of the study.
10. Eats 1 or fewer servings of fatty fish per week (e.g. salmon, tuna, mackerel, herring, anchovies, etc.)
11. Subject is willing to take the study multi-vitamin/mineral supplement for 30 days prior to starting investigational product and during the 4 month intake of investigational product.
12. Use of effective method of contraception by females of childbearing potential 30-days before the screening visit and agree to continue to practice that acceptable method of contraception for the duration of her participation in the study. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they become sexually active), transdermal patch, or any double barrier method including a vasectomized sexual partner. Women who have had a hysterectomy (partial or total) or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal for at least 1 year prior to Visit 1 are not considered to be of childbearing potential.

Exclusion Criteria

1. Subject has a known allergy or intolerance to any of the ingredients contained in the nutritional supplement.
2. Subject currently uses nicotine or has not quit using for at least 1 year.
3. Subject is taking an unapproved medication or has not been on a stable dose, for at least 8 weeks, of approved medication.
4. Subject who has undergone any type of surgery on their intestines that would interfere with product absorption, in the opinion of the investigator.
5. Subject is not willing to stop taking dietary/nutritional supplements for duration of study.
6. Subject is taking any dietary/nutritional supplements, not provided by the sponsor, within 30 days prior to investigational product administration.
7. Abnormalities in screening laboratory samples that the investigator would consider unstable/unsafe.

Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes